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ABSTRACT 
Kasten, Chelsea R. M.S., Purdue University, May 2014. Intra-nucleus accumbens shell 
injections of R(+)- and S(-)-baclofen bidirectionally alter binge-like ethanol, but not 
saccharin, intake in C57Bl/6J mice. Major Professor: Stephen L. Boehm, II. 
It has been proposed that the GABAB receptor subtype plays a role in alcoholism 
and alcohol use disorders (AUDs) (Cousins et al., 2002; Agabio et al., 2012). Specifically, 
the GABAB agonist baclofen has been looked at extensively in clinical and pre-clinical 
studies. In various animal models of chronic and intermittent consumption, baclofen has 
been shown to both increase (Petry, 1997; Smith et al., 1999; Czachowski et al., 2006; 
Moore et al., 2007) and decrease (Colombo et al., 2000; 2002; 2005; Stromberg, 2004; 
Moore et al., 2009) drinking. A critical issue in determining pharmacological effects of a 
drug is using the appropriate animal model. The drinking-in-the-dark (DID) model, 
developed by Rhodes et al. (2005, 2007), produces high levels of drinking in a binge-like 
paradigm and has been used to assess many pharmacological targets (e.g. Kamdar et al., 
2007; Gupta et al., 2008; Moore et al., 2007; 2009).  
While DID produces high-levels of binge drinking, it is unclear what areas of the 
brain are involved in this behavior. A direct way to target areas that are believed to be 
involved in the circuitry of particular behaviors is through microinjection of drugs 
(Kiianmaa et al., 2003). Of particular recent interest involving motivated behaviors and 
addiction is the nucleus accumbens (Acb) (Everitt & Robbins, 2005); specifically the
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 accumbens shell (AcbSh) (e.g. Rewal et al., 2009, 2012; Nie et al., 2011; Leriche et al., 
2008).  
The current study aimed to investigate the role of GABAB receptors in the AcbSh 
by examining the ability of two different enantiomers of baclofen to alter ethanol and 
saccharin intake in male C57BL/6J (B6) mice. B6 mice underwent bilateral cannulation 
surgery targeting the AcbSh. After 48 hours of recovery time, animals began a five day 
Drinking-in-the-Dark (DID) procedure where they received 20% ethanol or 0.2% 
saccharin for two hours, three hours into the dark cycle, each day. Throughout the five 
drinking sessions, animals were kept in home-cage locomotor activity chambers to 
monitor activity throughout the drinking cycle. Day 4 drinking was immediately preceded 
by a mock microinjection, whereas Day 5 drinking was immediately preceded by a drug 
microinjection. Microinjection of one of five doses of baclofen was given in ng/side 
dissolved in 200 µl of aCSF (aCSF alone, 0.02 R(+)-, 0.04 R(+)-, 0.08 S(-)-, or 0,16 S(-)-
). Intake was recorded every twenty minutes on Days 4 and 5. Retro-orbital sinus blood 
samples were taken from ethanol animals immediately following the Day 5 drinking 
period to determine blood ethanol concentrations (BECs). 
A one-way ANOVA on total Day 4 ethanol consumption revealed no baseline 
differences between dose groups. A one-way ANOVA on total Day 5 ethanol 
consumption revealed that the 0.04 R(+)- baclofen dose reduced total drinking, but the 
0.16 S(-)- baclofen dose increased total drinking (p’s<0.05). This pattern was reflected in 
the BECs; 0.04 R(+)- baclofen reduced BECs, whereas 0.16 S(-)- baclofen increased 
BECs (p’s<0.05). These results were also time-dependent, with R(+)-baclofen reducing 
drinking in the first 20 minutes of the session and S(-)- increasing drinking in the last 40 
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minutes of the session. There were no effects on saccharin intake. An issue with the 
locomotor activity boxes led to unreliable locomotor activity counts. However, because 
there were no drug effects on saccharin consumption, it was concluded that locomotor 
effects did not contribute to the decreases or increases in ethanol consumption. These 
results further implicate the role of GABAB receptors in modulating ethanol intake. The 
bidirectional effects shown highlight the importance of considering enantioselective drug 
effects when interpreting data. Finally, these results also support previous conclusions 
that the AcbSh plays an important role in modulating use of drugs of abuse, but not other 
reinforcers. 
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CHAPTER 1 INTRODUCTION 
1.1 Neural Circuitry 
 GABA and ethanol interactions have been repeatedly supported through a broad 
spectrum of research. For example, extrasynaptic GABAA receptors are known to be 
sensitive to moderate doses of ethanol (Wallner et al., 2003; Rewal et al., 2009), ethanol 
affects GABA function through interactions with neural circuits that influence GABA 
release both pre- and post-synaptically (Breese et al., 2006; Roberto et al., 2003), and that 
such interactions between GABA and ethanol are regionally specific within the brain 
(Breese et al., 2006; Rewal et al., 2009; Rewal et al., 2012; Nie et al., 2011; Leriche et al., 
2008; Koob et al., 1998).   
 Generally, the focus of acute ethanol reinforcement has been in areas that are 
involved in the dopaminergic system and include prevalent GABA receptors. These areas 
include the mid-brain, basal forebrain, amygdala, and the Acb. Leriche et al. (2008) 
sought to characterize GABA neurons in the neurocircuitry known to be involved in 
motivated behavior, including the medial prefrontal cortex, central division of the 
extended amygdala and the Acb. Male Sprague-Dawley rats were given seven days of 
intra-gastric distilled water with administration of distilled water or a 2.5 g/kg dose of 
ethanol on the eighth day. Brains were taken two hours later and Fos-positive cells were 
counted in six areas of interest. The ethanol animals showed increased Fos-positive cells
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as compared to the water and intra-gastric naïve animals in the prelimbic cortex, 
infralimbic cortex, AcbSh, bed nucleus of the stria terminalis, and lateral central 
amygdala. The Acb core showed no difference in Fos-positive cells between groups. 
GAD mRNA hybridization was then done to quantify reactive GABA cells in these areas. 
In the AcbSh, more than 80% of the Fos-reactive cells were GABAergic, solidifying the 
important role GABA neurons of the AcbSh play in response to ethanol. 
Generally, the Acb is known for its involvement in reward, pleasure, addiction, 
aggression, and fear (Ikemoto & Panskepp, 1999). The AcbSh is specifically identified as 
playing an important role in locomotor stimulation directed at acquiring food and drug 
reinforcers, as well as motivation to obtain reinforcers (Everitt and Robbins, 2005). 
Multiple neurons, receptors, and neurotransmitters populate the AcbSh. These include a 
small population (~1-2%) of acetylcholine (ACh) neurons, most of which are 
interneurons, a large population of dopaminergic neurons, NMDA and AMPA receptors, 
and GABAergic medium spiny neurons (Di Chiara et al., 1994). Dopaminergic feedback 
loops between the AcbSh and VTA, Acb core, and dorsal striatum are considered to be 
important in addiction circuitry, with the Acb receiving dopaminergic projections to its 
GABAergic cells (Koob et al., 1998) The AcbSh also receives glutamatergic inputs from 
the prefrontal cortex and hippocampus and GABAergic outputs to the hypothalamus, 
brain stem, and ventral globus pallidus (Everitt & Robbins, 2005). While Everitt & 
Robbins (2005) discusses the GABAergic projection from the ventral global pallidum, 
first characterized by Dray and Oakley (1978) and further reviewed by Mogenson and 
Nielsen (1983), the model neglects to show the strong GABAergic projection from the  
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Acb to the ventral tegmental area (VTA) (Kalivas et al., 1993), The VTA and ventral 
pallidus have been directly implicated in various addiction paths (Bardo, 1998) (Figure 
1).  
To date, few studies have looked at the ability of directly interfering with GABA 
in the AcbSh to affect ethanol intake in preclinical models of consumption. The following 
studies have seen promising results on the ability of intra-AcbSh extrasynaptic GABAA 
receptors to moderate ethanol intake and the reinforcing effects of ethanol. Rewal et al. 
(2009) interfered with GABAA receptors containing the α4 subunit in the Acb core or 
shell using a viral microinjection which reduced α4 expression through mRNA 
interference. Viral knockdown of α4 in the Acb shell, but not core, reduced ethanol 
consumption and active lever pressing as compared to the sham virus injected group. 
Sucrose consumption and active lever pressing was not altered following viral injections 
into the core or shell. Nie et al. (2011) saw similar reductions in ethanol drinking 
following interference of extrasynaptic δ-containing GABAA receptors from viral vector 
injections targeting δ-mRNA expression. Again, viral knockdown of δ in the shell, but 
not core, reduced ethanol consumption compared to the sham group. These results also 
did not extend to sucrose consumption, suggesting that the role of the AcbSh in 
reinforcement seeking is specific to drugs of abuse.  
 As previously mentioned, GABA is known to be widely prevalent within the Acb, 
and GABAB receptors represent a substantial target. An entire third of the GABA 
receptors in the Acb are GABAB receptors (Bowery et al., 1987). In the rat brain, the Acb 
has one of the highest levels of μmol of GABA/g of tissue (Balcom et al., 1975). Within 
the human brain the Acb falls into middle ground for levels of GABA binding sites 
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quantified in fentomoles (fmoles) out of regions in the cortex and subcortical nuclei 
(Lloyd et al., 1977). The cerebellar cortex binds the highest fmoles of GABA per mg of 
protein at 328.1, the substantia alba binds the lowest at 1.7 fmoles, and the Acb binds 
58.1 fmoles. A higher level of GABA terminals in the Acb has also been seen in  two 
strains of alcohol preferring rats versus  their respective non-preferring strains   eight 
weeks after the end of a four week drinking period (Hwang et al., 1990). The authors 
propose that, as long-term GABA fluctuations are not related to drinking itself, it appears 
that the GABA increase is specific to alcohol preference seen in P and HAD rats as well 
as B6 mice. However, Hwang et al. (1990) took no baseline measures of GABA. 
Therefore GABA levels may have increased following drinking or held constant from 
baseline to post-drinking. This still suggests that there are differences in GABA receptor 
terminals in the Acb between animals that do and do not prefer ethanol. 
 All of this information taken together suggests multiple things. 1) There is an 
important interaction between GABA and ethanol. 2) GABA is widely prevalent in the 
Acb, with both GABAA and GABAB receptors being present. 3) Altering extrasynaptic 
GABAA receptors in the AcbSh leads to reductions in drinking. Further, GABAA and 
GABAB receptors are known to “cross-talk” to influence each other’s binding properties 
and signal activities (Balasubramanian et al., 2004). While the mechanisms of this cross-
talk are obscure, and a review of the literature is beyond the scope of this project, 
knowing that GABAA and GABAB receptors interact further supports the hypothesis that 
GABAB receptors are involved in alcohol consumption. This project sought to identify 
the role that GABAB receptors of the AcbSh play in ethanol consumption, with the 
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hypothesis that directly altering intra-AcbSh GABAB receptor activation via 
microinjection of a GABAB agonist will alter ethanol consumption 
1.2 Baclofen 
 The GABAB agonist baclofen has been of great interest in treating AUDs , 
although the only approved uses are as a muscle relaxant and to treat spasticity in 
neurological disorders (Iversen et al., 2009). GABAB receptors are heterodimer 
complexes comprised of mutually dependent B1 and B2 subunits (White et al., 1998). As 
a direct agonist, baclofen binds to the B1 subunit of active and inactive receptors as 
GABA would (Pin et al., 2004; Urwyler et al., 2003). GABAB receptors are located pre- 
and postsynaptically. Presynaptic receptor activation inhibits neurotransmitter release via 
modulation of high-voltage-activated Ca++ channels. Such suppression may increase or 
decrease system inhibition, as autoreceptors are also present that decrease the release of 
GABA itself. Overall inhibition of neuronal excitability is left to postsynaptic GABAB 
receptors through G-coupled protein activation that leads to K+ channel activation and 
down regulation of adenylyl cyclase (Bernard et al., 2001; Agabio et al., 2012). 
 Baclofen comes in three forms; an R-enantiomer, S-enantiomer, and the racemate, 
which is a combination of both R- and S-baclofen. While baclofen has been shown to be 
a promising prospect for treatment of AUD both pre-clinically and clinically, it is very 
rarely specified which form of baclofen has been used. In the following studies, clinical 
and NIH trials would have used the racemic compound. Apart from the preliminary data, 
it is unclear which compounds were used in preclinical drinking models. 
In European populations, baclofen rapidly suppresses the alcohol withdrawal 
syndrome (AWS) and delirium tremens, symptoms which did not recur after 
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discontinuation of the drug in an open clinical study (Addolorato et al., 2003). Baclofen 
has also been shown to be just as effective as diazepam in reducing AWS symptoms in 
alcohol-dependent patients with moderate to severe AWS (Addolorato et al., 2002). 
Baclofen has been shown to reduce craving and anxiety while increasing alcohol 
abstinence in alcohol-dependent subjects (Addolorato et al., 2000). Finally, baclofen has 
been shown to be a safe medication for patients with liver cirrhosis compared to other 
anti-craving drugs that possibly worsen liver disease, such as naltrexone (Addolorato et 
al., 2009). None of these studies have addressed whether baclofen in itself is an addictive 
drug. 
While many reviews highlight the inability of baclofen to produce effects in non-
European populations, few clinical studies have been done in US populations to 
investigate baclofen’s alleviation of AUD symptoms. One initial open label study found 
that baclofen was well-tolerated as it reduced anxiety, craving, number of drinks per 
drinking day, and number of heavy drinking days while increasing number of abstinent 
days (Flannery et al., 2004). However, these conclusions were drawn from a final sample 
size of 4 individuals. A much larger US clinical trial run a few years later showed once 
again that baclofen was well-tolerated, but was unable to increase the number of abstinent 
days in heavy drinkers, time to first drink during drinking bouts, or time to relapse to 
heavy drinking over the placebo condition (Garbutt et al., 2010). Conversely, one small 
clinical study showed the ability of baclofen to reduce alcohol withdrawal symptoms in 
hospital inpatients at high risk for AWS (Lyon et al., 2011). Current FDA trials include 
recruiting participants to test the safety and efficacy of baclofen for treating alcohol 
withdrawal symptoms, abstinence during and after treatment, and to reduce heavy 
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drinking. Baclofen is also being investigated for use as a combination therapy with 
lorazepam to reduce withdrawal symptoms, and as a combination with naltrexone to 
reduce symptoms that naltrexone does not treat, like anxiety and irritability 
(clinicaltrials.gov; search term “lioresal”).  
Pre-clinically, baclofen has been shown to reduce the “alcohol deprivation effect” 
in sP rats (Colombo et al., 2003; 2006), reduce operant responding and amount of self-
administered alcohol in fixed ratio operant paradigms (Anstrom et al., 2003; Janak et al., 
2003; Besheer et al., 2004; Maccioni et al., 2005; Liang et al., 2006; Walker et al., 2007), 
lower the breakpoint of responding for ethanol in a progressive ratio procedure in alcohol 
preferring rats (Maccioni et al., 2008), and suppress extinction responding via systemic 
injections (Colombo et al., 2003). Studies looking specifically at baclofen’s effect on 
alcohol intake have shown mixed results. Decreases (Colombo et al., 2000; 2002; 2005; 
Stromberg, 2004) and increases (Petry, 1997; Smith et al., 1999; Czachowski et al., 2006) 
have been seen in drinking following acute or chronic systemic injections of baclofen in 
rodents. Our lab has previously seen an increase of consumption in B6 mice with acute 
systemic injections of baclofen (Moore et al., 2007). We have also seen a decrease in 
drinking when baclofen was microinjected into the anterior VTA, but no effect when 
injected into the posterior VTA (Moore et al., 2009). 
As mentioned, while these studies have all used baclofen, they do not specify 
which isomer of baclofen has been used. The racemic compound of baclofen, used in 
clinical studies and approved for use for anti-spasticity, can be separated into two 
different enantiomers. The R-enantiomer is 100 times more active than the S-enantiomer 
(Spahn et al., 1987; Zhang et al., 2011). Many chemical studies looked at the synthesis of 
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each baclofen compound, yet there are not many studies that quantify what each 
compound does behaviorally. Olpe et al. (1978) sought to compare the R- and S- 
enantiomers with the racemate of baclofen in multiple tests. They found that the racemate 
and the R-enantiomer of baclofen dose-dependently inhibited the patellar, flexor, and 
linguo-mandibular reflexes and lowered blood pressure in cats. The S-enantiomer had no 
effects on reflexes even at the highest doses, and had minimal effects on blood pressure. 
The racemic baclofen was actually less potent than the R-enantiomer at reducing the 
patellar reflex, whereas racemic and R-baclofen were equipotent at reducing the flexor 
and linguo-mandibular reflexes. Both the racemate and R-enantiomer of baclofen dose-
dependently protected mice from electroshock-induced seizures, while S-enantiomer 
doses of up to 100 mg/kg had no effect on convulsions. Further, Paredes and Agmo (1989) 
showed S-baclofen to be ineffective at inhibiting sexual behavior, even when given at a 
dose 40 times higher than the minimally effective R-baclofen dose. The racemic 
compound was half as active as the R- enantiomer, yet both reduced sociosexual-specific 
locomotor activity and motor execution while S-baclofen remained completely inactive.  
Fromm et al. (1990) showed that it takes a S-baclofen dose 20 times larger than the least 
effective R-baclofen dose to depress response of the trigeminal nucleus oralis and that S-
baclofen actually reduces response to R-baclofen in the periphery, but not the CNS.  
Such results question the effects of the S-enantiomer, as it appears to have no 
effect, lowered effects, or even antagonistic effects on various behaviors and reflexes. 
Olpe et al. (1978) suggest that the less active S-enantiomer may play a role in 
potentiating the action of the R-enantiomer without being active itself, yet Fromm et al. 
(1990) show that not only is S-baclofen active at higher doses, they also believe it inhibits 
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the actions of R-baclofen in certain cases. The enantioselective actions of baclofen are 
different depending on the behavior being observed, highlighting the need to consider 
enantioselective aspects of drug action when considering therapeutic uses of the drug 
(Jamali et al., 1989) and choosing an appropriate model of behavior to therapeutically test 
drugs (Fromm et al., 1990). 
Preliminary studies within our lab have shown an effect of both R(+)- and S(-)- 
baclofen on ethanol and saccharin consumption. B6 mice were exposed to a 20% ethanol 
solution for two hours, three hours into the dark cycle, for 5 days. On Day 4 a habituation 
saline injection was given and on Day 5 a dose of baclofen was given. Animals were 
matched by intake for dose groups on Day 5. Injections took place immediately before 
bottles on, with intake readings at 1hr and 2hrs on Days 4 and 5. Retro-orbital sinus blood 
samples were collected on Day 5 immediately after access. Dose-responses 
determinations were also performed using a 0.32% saccharin solution in place of the 20% 
ethanol solution. 
R(+)- baclofen was given in doses of 0, 1, 3, or 10mg/kg. Following a significant 
one-way ANOVA, Dunnett’s post-hoc tests revealed the 10mg/kg dose of baclofen 
reduced total 2hr ethanol intake and ethanol intake in the first hour compared to the 
0mg/kg group (p’s < .05). This reduction of intake was reflected in the pattern of blood 
ethanol concentrations (BECs), with the 10mg/kg dose reducing BECs (p < .05BECs 
were strongly correlated with total 2 hour ethanol intake; r(39) = .922, p < .001 (data not 
shown).R(+)- baclofen also reduced total 2hr saccharin intake at the 10mg/kg dose (p 
< .05) . This dose effect was not specific to hour; the 10mg/kg dose reduced intake at 1hr 
and 2hr readings (p’s < .05) . 
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S(-)- baclofen was given in a dose of 0, 1, 3, 10, or 30mg/kg on Day 5 of drinking. 
The higher 30mg/kg dose was included due to the lower potency of the S(-)-baclofen 
enantiomer. Whereas R(+)-baclofen decreased ethanol intake, S(-)-baclofen increased 
ethanol consumption in the second hour of access at the 3 and 10mg/kg dose (p < .05), 
and trended towards increasing intake at the 1mg/kg dose (p = .05). No significant effects 
on total ethanol drinking or BECs were evident. Also contrary to R(+)-baclofen, S(-)-
baclofen did not affect total or hourly saccharin intake . These results show that the 
baclofen enantiomers work in opposing directions while altering ethanol intake.  
1.3 Drinking-in-the-Dark 
To target the neural circuitry that may be involved in this drinking phenomenon, 
microinjection work was carried out using the same DID paradigm used in the 
preliminary data. This model offers many advantages and few disadvantages. DID is a 
method that achieves high levels of drinking in a binge-like paradigm by introducing 
ethanol three hours into the dark cycle with a two hour access period (Rhodes et al., 2005; 
2007). The DID paradigm allows for many advantages over 24-hour access drinking. In a 
relatively short period of time B6 mice reliably ingest enough ethanol to reach 
pharmacologically relevant BECs of over 1mg/ml, as evidenced in the preliminary data. 
These levels are met without having to implement food or water restriction. This, 
combined with the simplicity of the design, allows the experimenter to easily assess 
drinking in a high volume of animals quickly and efficiently while collecting reliable and 
meaningful data (Rhodes et al., 2005; 2007).  Ethanol intake using DID procedures is 
moderately to strongly correlated with two-bottle choice preference drinking, ethanol-
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induced hypothermia, and locomotor activity, and negatively correlated with conditioned 
taste aversion (Rhodes et al., 2007) 
 Because DID produces pharmacologically relevant ethanol intakes and behavioral 
and physiological changes it has been used as a model to screen potential AUD 
treatments. Kamdar et al. (2007) used the DID paradigm to show that naltrexone reduced 
ethanol drinking, but not water or sugar water consumption, while the dopaminergic drug 
GBR 12909 reduced ethanol and sugar water consumption. The glutamatergic drugs 
acamprosate and MPEP have been shown to dose-dependently reduce ethanol drinking 
while only reducing water and sugar water intake at higher doses in the DID paradigm 
(Gupta et al., 2008). The GABA system has also been shown to play a role in fluid intake 
under DID procedures. The GABAA agonists gaboxadol (THIP) and muscimol have been 
shown to reduce ethanol and water intake, while the GABAB agonist baclofen 
specifically increased ethanol consumption without affecting water intake (Moore et al., 
2007). 
 The current study aimed to investigate the role of GABAB receptors in the AcbSh 
in ethanol consumption in B6 mice. This goal was undertaken by establishing DID, then 
giving microinjections of either R(+)- or S(-)- baclofen directly into the AcbSh with the 
hypotheses that R(+)- baclofen would decrease ethanol consumption and S(-)- baclofen 
would increase ethanol consumption. I elaborate further on these hypotheses in the 
specific aims section.  
1.4 Specific Aims 
1. Reduce established drinking by microinjecting R(+)- baclofen into the AcbSh. 
Preliminary data have shown that R(+), the more potent enantiomer of the baclofen 
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racemate, decreases ethanol and saccharin consumption following acute systemic 
injection (unpublished data).  
2. Increase established drinking by microinjecting S(-)- baclofen into the AcbSh. 
Preliminary data have shown that S(-), the less potent enantiomer of the baclofen 
racemate, increases ethanol, but not saccharin, consumption following acute systemic 
injection (unpublished data). 
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CHAPTER 2 EFFECTS OF INTRA-ACBSH BACLOFEN ON ETHANOL AND 
SACCHARIN INTAKE AND LOCOMOTION 
2.1 Materials and Methods 
2.1.1 General Design 
The design of this project is shown in Table 1. In brief, male B6 mice underwent 
surgery for bilateral cannulation of the AcbSh. Following 48 hours or longer of recovery, 
mice began a five-day DID procedure where 20% ethanol or 0.2% saccharin was 
available for two hours, three hours into the dark period each day. On Day 5, animals 
received one of five possible microinjection doses; 0.02 or 0.04µg R(+)-baclofen, 0.08 or 
0.16µg S(-)-baclofen, or artificial cerebrospinal fluid (aCSF) (Fig. 2). 
2.1.2 Subjects 
Male B6 mice were bred in-house. Breeders for our colony were obtained from 
Jackson Labs (Bar Harbor, ME) and replaced every few months by new breeder pairs 
purchased from Jackson Labs. A total of 127 animals were used in this study. Within 
each reinforcer group (saccharin or ethanol) the same aCSF control group (dose = 0.0 μg) 
was used for each drug (R- or S- baclofen) to reduce the number of animals used in this 
project (see Fig. 2).  
Animals received food at all times and water ad lib apart from during 
implementation of DID. Lights were kept on a reverse light-dark schedule with lights off 
at 8am. Animals were group housed until the time of surgery, after which time they were 
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individually housed. Animals were at least 58 days of age at the time of surgery, and at 
least 60 days of age at the time DID started. Procedures were approved by the IUPUI 
School of Science Institutional Animal Care and Use Committee and conformed to the 
Guide for the Care and Use of Laboratory Animals (The National Academic Press, 2003). 
2.1.3 Drugs 
Ethanol (190 proof) was obtained from Pharmco, Inc (Brookfield, CT). The 20% 
v/v ethanol solution was prepared with tap water. Saccharin (≥99%) was obtained from 
Sigma Aldrich (St. Louis, MO) and was dissolved in tap water to make a 0.2% saccharin 
solution.  R(+)- and S(-)- baclofen was obtained from Sigma Aldrich (St. Louis, MO). 
Baclofen was dissolved in aCSF (Sigma Aldrich, St. Louis, MO) to doses of  0.02 and 
0.04 µg for R(+)-baclofen, and 0.08 and 0.16 µg for S(-)-baclofen. Justification of these 
doses is discussed below. Unadulterated aCSF was used as the 0.0 µg control group. 
Drug was delivered in a volume of 200 nl per side with a flow rate of 382 nl/min. 
Our goal in choosing doses for this study was to find the highest drug dose that 
did not cause an effect on ethanol intake, as well as the lowest dose that did cause an 
effect on ethanol intake. Therefore, all doses were piloted in ethanol drinking animals 
following the same methodology discussed below. 
Initial R(+)-baclofen doses for this study were based on those used by Boehm et 
al. (2002), which were chosen for their ability to cause ethanol-induced locomotion when 
ethanol was given via i.p. injections, as well as Moore et al. (2009), which showed that 
both a 0.01 and 0.02 μg dose of baclofen inject into the anterior VTA were able to reduce 
drinking. Three doses of R(+)-baclofen were piloted (n=3 for each pilot group); 0.01, 
0.02, and 0.04 µg/side. The 0.04 µg/side dose appeared to reduce drinking, and was 
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therefore kept as a final dose. Neither 0.01 nor 0.02 µg/side appeared to reduce drinking, 
so 0.02 µg/side was chosen as the secondary dose because it was the highest dose to not 
produce an effect. 
S(-)-baclofen doses were expected to be higher than R(+)-baclofen doses, because 
S(-)- is the less potent enantiomer. Piloting appropriate doses for S(-)-baclofen began by 
using the highest agreed-upon dose of 0.32 µg/side (n=3). This dose appeared to 
incapacitate the animals, and was therefore cut in half to 0.16 µg/side. The 0.16 µg/side 
appeared to potentially increase drinking in the pilot group (n=3), and was kept as one of 
the two final doses. To choose the second final dose, 0.08 µg/side and 0.24 µg/side doses 
were piloted (n=3 for each group). The 0.24 µg/side did not appear to increase ethanol 
intake more than the 0.16 µg/side dose, therefore the 0.08 µg/side dose was chosen 
because it appeared to be the highest dose that would not affect intake. 
These pilot doses led to final doses of 0.02 and 0.04 µg/side of R(+)-baclofen and 
0.08 and 0.16 µg/side of S(-)-baclofen. Animals used to pilot the final doses were 
included in the final group sizes for these doses. 
Dose groups were randomly assigned when possible. Due to microinjection pump 
availability, a maximum of two dose groups could be tested at a time.. When five or more 
animals were tested, they were split into two dose groups that were matched by Day 4 
drinking. Animals were tested in every dose group before groups were filled out. Means 
for Day 4 drinking were kept constantly updated to make sure that baseline drinking did 
not differ as animals were being assigned groups throughout the course of the study. 
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2.1.4. Surgery 
The shell of the Acb was targeted (coordinates of X: ±0.63, Y: 1.18, Z: 2.0) 
through bilateral cannulation. Surgical procedures followed those currently outlined in 
our approved IACUC protocol, as described in Moore et al. (2009). Briefly, mice were 
anesthetized using a ketamine/xylazine cocktail (1mL ketamine, 0.1 mL xylazine, and 8.9 
mL sterile saline). Once anesthetized, the animal was placed in a Kopf stereotaxic 
alignment system (Tujunga, CA). The animal’s head was shaved and a small incision 
made from approximately bregma to lambda. The skull was sterilized with 100% ethanol 
and Nolvasan three times. Animals’ eyes were kept moist with commercially available 
tear ointment. For accuracy, the distance between bregma and lambda was measured and 
divided by 4.21mm, the published average distance between lambda and bregma for B6 
mice (Frankling and Paxinos, 1997). The previously mentioned coordinates were then 
adjusted by that percentage and two holes were drilled at the adjusted coordinates for 
bilateral placement of guide cannula. A third hole was drilled for placement of a screw to 
anchor the skull cap, which was placed after the cannulae were simultaneously lowered 
into the brain to a depth of 2mm. After placement of the cannula and screw. Stoelting 
clear dental cement (Fisher Science, Hampton, NH) was applied to the exposed skull to 
secure the guide cannulae and protect the skull. After the cement dried, animals were 
placed in a cage (with a special flat top to accommodate the cannulae) on a heating pad 
until they recovered from the anesthesia. Bedding, food, and water were reintroduced 
once the animal was up and moving then the animals was returned to the reverse light-
dark room. 
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2.1.5. DID Procedures 
Following surgery, animals had at least 48 hours of recovery before the 
introduction of DID. The length of recovery time was varied between 48 hours to six 
days for the first few cohorts tested, and it was found that 48 hours of recovery led to 
optimal consumption during DID following surgery. During the recovery time, the 
cannulae stylets were removed daily to prevent obstruction. While daily restraint was 
necessary to move the stylets, timed restraint to habituate the animal to the microinjection 
procedure began on Day 3 of DID (Table 1). Stylet removal and restraint occurred 
immediately prior to bottles-on time to acclimate animals to the restraint stress of the 
microinjection. 
All drinking took place in home-cage locomotor boxes (Opto M3 13” x 9” Mouse 
Cages, Columbus Instruments, Columbus, OH). DID procedures were slightly modified 
from that of Rhodes et al. (2005, 2007) and Moore et al. (2007). Three hours into the dark 
cycle animals received two hours of access to either a 20% ethanol solution or a 0.2% 
saccharin solution in 10mL ball-bearing sipper tubes for five days, with access to only 
water for the remaining 22 hours. The saccharin group was included to act as a control 
group for drug effects on alternative reinforcers. The home cage locomotor boxes were 
used to account for competing locomotor sedation. As previously mentioned, baclofen 
shows a sedative effect in ethanol-naïve animals (Cryan et al., 2004). Using the home-
cage monitors allowed a count of the animals’ movement to speak to any effects of 
sedation by allowing characterization of the animals’ typical movement patterns and 
pattern of movement following drug injection.  
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Restraint took place on Day 3 and mock microinjections took place on Day 4. 
Drug was administered via microinjection on Day 5. In aim 1, R(+)- baclofen was 
microinjected with the hypothesis that it would reduce ethanol consumption. In aim 2, S(-
)- baclofen was microinjected with the hypothesis that it would increase ethanol 
consumption. On Days 1-3, fluid volumes were recorded immediately before and after 
fluid access. On Days 4 and 5, fluid volumes were recorded immediately before and after 
fluid access, as well as every 20 minutes during fluid access to capture the time course of 
the drug effects on Day 5. 
2.1.6. Intra-AcbSh Microinjections 
Guide cannulae, stylets and tubing to make microinjectors were obtained from 
Small Parts Inc. (Miami Lakes, FL). Guide cannulae were made of 25-gauge stainless 
steel tubing, cut to 15 mm. Stainless steel wire (0.0095 inch) was used to make stylets to 
be placed inside the guide cannulae to prevent obstruction. Microinjectors were made 
from two sections of stainless steel tubing: a 30-mm section of 32-gauge tubing was 
inserted into a 30-mm section of 25-gauge tubing so that 18 mm extended. The two 
pieces were soldered together and checked for leaks.  
Two segments of PE-20 tubing were attached to each microinjector and loaded 
with aCSF or one of the four baclofen doses. The other ends of the tubing were fitted 
over two 10-µl Hamilton glass syringes (Hamilton Co., Reno, NV, USA) filled with 
distilled water. The syringes were placed on a Cole-Parmer (74900-Series) dual infusion 
pump. For the microinjection, mice were grasped by the scruff of the neck using the 
thumb and forefinger of the left hand. The microinjectors were slowly inserted and held 
in place by the thumb and forefinger of the right hand, extending 3mm past the guide 
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cannula to hit the AcbSh. Fluid was microinjected at a rate of 382 nl/min, which took 
about 40 seconds to inject the 200nl of fluid. Microinjectors were held in place for 
another 30 seconds to allow time for the drug to diffuse from the microinjector tips. The 
microinjectors were then slowly removed and animals were placed back into their cages. 
2.1.7. Blood Ethanol Concentrations 
On the fifth day of access, retro-orbital sinus blood samples were collected from 
every animal given access to ethanol immediately following bottle removal using 50 µL 
heparinized microcapillary tubes to verify intake. Samples were immediately placed in 
the centrifuge and plasma and decanted. The samples were stored at −80°C until time of 
assay, at which point they were analyzed with an Analox Alcohol Analyzer (Analox 
Instruments, Lunenburg, MA) to determine BEC. 
2.1.8. Histological Verification of Cannulae Placement 
Immediately following the end of drinking on Day 5, animals were euthanized by 
cervical dislocation. Brains were extracted and flash-frozen using methylbutane (−25°C). 
Brains were stored in the -20°C freezer until they were sliced using a cryostat, thaw-
mounted on slides, thionin stained, and cover slipped. Placement of cannulae was 
inspected and verified by two different blind experimenters. 
2.1.9. Statistical Analysis 
Statistical analyses only included animals with histologically verified bilateral hits 
of the AcbSh (detailed in Tables 2 and 3). Ethanol and saccharin results were analyzed 
separately. Within the ethanol and saccharin groups, R(+)- and S(-)- baclofen were 
analyzed together because they shared a control group. Significance level for all overall 
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analyses was set at p < .05, with all post-hoc tests being corrected for multiple 
comparisons.  
 Drinking acquisition on Days 1-4 was assessed using a one-way analysis of 
variance (ANOVA) with days as the within-subject factor. Tukey’s post-hoc tests were 
used when warranted. A one-way ANOVA was used to analyze total Day 4 drinking and 
locomotor activity with dose as the between-subjects factor to verify that total baseline 
drinking and locomotion following mock microinjection did not vary between groups. 
Following this verification, dose effects on total Day 5 drinking and locomotion were 
assessed using a one-way ANOVA with dose as the between-subjects factor. For the 
ethanol animals, a one-way ANOVA with dose as the between-subjects factor was also 
used to assess dose effects on BEC following intake, as well as a bivariate Pearson’s 
correlation between total intake and BEC. Post-hoc independent samples t-tests were 
used for all necessary post-hoc tests on total 2hr consumption and BEC data.  
 To assess for dose-effects on time course of intake and locomotion, a two-way 
repeated measures ANOVA with dose as the between-subjects factor and time as the 
within-subjects factor was used. Day 4 intake and locomotion was assessed first to verify 
that there were no baseline differences in time course between each dose group. 
Following this verification, Day 5 data was assessed. One-way ANOVAs were used at 
each time-point with dose as the between subjects factor as post-hoc tests for a significant 
two-way ANOVA. Tukey’s post-hoc tests were used for any significant one-way 
ANOVA effect.  
 Due to a problem with the locomotor equipment that was discovered midway 
through the experiments (discussed below), more analyses were used to properly assess 
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the locomotor activity data. Total Days 1-5 locomotion for each dose independently was 
analyzed by a one-way ANOVA, with Tukey’s used as the post-hoc test. A two-way 
repeated measures ANOVA with Day and time-bin as within-subjects factors was used to 
analyze Day 4 and Day 5 locomotion for each dose independently. This analysis was also 
used to compare drinking data to locomotor data. Paired samples t-tests were used as 
post-hocs for repeated measures tests. 
2.2 Results 
2.2.1. Ethanol Consumption 
Animal usage is detailed in Table 2. Seventy-eight total animals were included in 
all aspects of the ethanol portion of this study. Out of those animals, 52 completed the 
study and were in the appropriate dose groups, with 44 of those animals being successful 
hits, giving a hit rate of 84.62% within this subset of animals. Only the 44 successful 
animals are included in the following analyses. 
The ANOVA on Days 1-4 acquisition of drinking revealed a significant effect; 
F(3,175) = 3.21, p < .05 (Fig. 3A). Tukey’s post-hoc revealed that Day 2 drinking was 
significantly higher than Day 3 drinking (p < .05). Total Day 4 drinking following the 
mock injection did not differ between groups; F(4,43) = .322, p > .05, data not shown. 
There were significant dose effects on total Day 5 ethanol intake following the 
microinjection; F(4,43) = 10.14, p < .001. Independent samples t-tests corrected for 
multiple comparisons revealed that the 0.04 µg R(+)-baclofen group drank significantly 
less than the aCSF group, whereas the 0.16 µg S(-)-baclofen group drank significantly 
more than the aCSF group (p’s < .05) (Fig. 3B). This pattern was replicated in the BEC 
data, with the 0.04 R(+)- baclofen group showing significantly lower BECs than the 
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aCSF group, while the 0.16 S(-)- baclofen group showed significantly higher BECs 
immediately following ethanol intake (p’s < .05) (Fig. 3C). BECs and total two hour 
ethanol consumption were strongly correlated; r(43) = 0.834, p < .001 (Fig. 3D). 
The time course of ethanol intake was then statistically compared. For both 
analyses, Greenhouse-Geisser statistics are reported because Mauchly’s Test for 
Sphericity was significant (p’s < .05) A dose*time bin repeated measures ANOVA on 
Day 4 time course intake verified that there were no baseline differences between dose 
groups; F(11.38, 110.90) = 1.169; p > .05 (Fig. 4A). The time course of ethanol intake 
following micro-injection on Day 5 was significantly different between dose groups; 
F(16.12, 153.18) = 1.931, p > .05. One-way ANOVAs at each time-point revealed that 
differences between doses existed at the 0 to 20, 81 to 100, and 101 to 120 minute time 
bins (p’s < .05). Tukey’s post-hocs revealed that at 0 to 20 minutes. The 0.04 µg R(+)- 
group drank significantly less than the aCSF group (p < .05). At 81 to 100 minutes. The 
0.16µg S(-)- group drank significantly more than the 0.02 and 0.04 µg R(+)- groups (p’s 
< .05). At the 101 to 120 minute time point, the 0.16 µg S(-)- group drank significantly 
more than the aCSF, 0.02, and 0.04 µg R(+)- groups (p’s < .05) (Fig. 4B). 
While the following statistical tests were not agreed upon in the project proposal, 
repeated measures ANOVAs analyzing the time course of drinking between Day 4 and 
Day 5 for each dose independently were used to confidently  compare drinking to 
locomotor activity. The ANOVAs revealed no main effects of time or day, nor was there 
an interaction for the aCSF and 0.16 S(-)- groups (p’s > .05) (Fig. 5A & 5E). The 0.02 
R(+)- group showed a main effect of day and time, with animals drinking less on the 
microinjection day and drinking being lower in the middle of the drinking session (p’s 
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< .05). There would have been an effect of day*time bin, except Mauchly’s Test for 
Sphericity was significant (p = .049) and Greenhouse-Geisser statistics indicated no 
interaction was present; F(1.99,15.918) = 2.99, p = .079 (Fig. 5B).  There was a main 
effect of day for the 0.04 R(+)- group, with animals drinking less overall on the 
microinjection day (p < .05). There was no main effect of time (p >.05). Again, a 
significant interaction of Day*Time bin was reduced by a significant Mauchly’s Test for 
Sphericity (p < .05), with the Greenhouse-Geisser correction not being significant; 
F(1.858,13.077) = 3.591, p = .06 (Fig. 5C). The 0.08 S(-)- group displayed no main 
effect of day, but a main effect of time, with higher drinking in the first and last 20 
minute bins (p < .05). There was an interaction of day*time; F(5,40) = 3.635, p < .01. 
Post-hoc, paired samples t-tests revealed that drinking on the microinjection day was 
significantly lower only at the 0-20 minute point; t(8) = 4.218, p < .01 (Fig. 5D). 
2.2.2. Ethanol Locomotion 
Midway through the experiment a malfunction in the Opto M3 home-cage activity 
monitors was noticed. The malfunction appeared to be a degradation in the equipment, 
with photobeam scanners slowly failing over time, resulting in inaccurate locomotor 
counts, with distance travelled being lower than what it should have been because broken 
photobeams were not registering locomotor counts. The slow breakdown of the system 
eventually resulted in complete failure, at which time a representative from Columbus 
Instruments came to replace a majority of the system. All of the ethanol aCSF, R(+)- 0.02, 
and R(+)- 0.04 animals as well as three of the S(-)- 0.16 animals, were tested before the 
equipment was fixed. Four S(-) 0.08 animals do not have locomotor data because the 
activity boxes had completely failed at the time of their testing. For the saccharin animals, 
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six aCSF, five R(+)- 0.02, and five R(+)- 0.04 animals were tested before the activity 
boxes were fixed. Further, because the failure was time dependent, the closer an animal 
was tested to the point of complete system failure, the more inaccurate their locomotor 
count may have been. Therefore, there is low confidence in the accuracy of those activity 
counts, especially as there is no way to account for when the system started to degrade 
and how it affected activity counts over time. Because of this issue, statistical analyses 
that focused on each independent dose group were used to minimize the variance due to 
equipment error in the data. A one-way ANOVA on Days 1-5 drinking, as well as a 
repeated measures ANOVA on Day 4 and 5 time course drinking, analyzed effects each 
dose independently. These analyses minimized equipment error variance by focusing on 
the relative difference between a few days’ time, where there would be minimal changes 
in equipment malfunction. In other words, comparing all Day 5 locomotion back to the 
previous day’s locomotor activity accounts for the absolute differences in locomotor 
scores between when the equipment was and was not working properly. 
As an example, a group tested before the equipment was fixed may have had a 
Day 4 score of 900 counts and a Day 5 score of 800 counts. A group tested after the fix 
may have had a Day 4 count of 12,000 and a Day 5 count of 11,900. So the absolute 
difference between groups on Day 5 is likely to be inaccurate at 11,000 counts, whereas 
the relative differences between each group for Day 4 and Day 5 is more accurate at 100 
counts each. Although the statistical analyses analyzed within groups will be used for 
discussion of the overall findings because they are the most credible,  between dose 
groups differences were statistically analyzed to uphold the expectations of the 
committee. 
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 One-way ANOVAs showed no differences between dose groups on total Day 4 
baseline locomotor scores or total Day 5 test locomotor scores (p’s > .05), data not shown. 
The day 4 locomotion dose*time bin ANOVA revealed no baseline differences between 
dose on the time course of locomotor activity. There were no main effects of time or dose 
(p > .05), data not shown. Using Greenhouse-Geisser statistics due to a significant 
Mauchly’s Test for Sphericity (p < .001), there was not a significant interaction between 
time bin and dose or main effects on Day 5 locomotion (p’s > .05) (Fig. 7A).   
 ANOVAs on Day 1-5 locomotor data for each dose revealed a significant effect 
of day for the aCSF, R(+)- 0.02, and S(-)- 0.08 dose groups (p’s < .01). Total locomotion 
on each day for the R(+)- 0.04 and S(-)- 0.16 groups was not significantly different (Figs. 
6C and 6E). Tukey’s post-hoc tests revealed that for the aCSF group, locomotion on 
Days 4 and 5 was significantly lower than on Day 1 (p’s < .05) (Fig. 6A). For the R(+)- 
0.02 group, locomotion on Days 3, 4, and 5 was significantly lower than Day 1 and 2 
locomotion (p’s < .05) (Fig. 6B). For the S(-)- 0.08 group, locomotion on Day 3 was 
lower than on Day 1, and Day 5 locomotion was lower than Days 1 and 2 (Fig. 6D). 
To confidently assess the time course of locomotor behavior, Day 4 time course 
locomotion was compared to Day 5 time course locomotion. There were no significant 
day*time-bin interactions or main effects of time or dose for the aCSF, S(-)- 0.08, or S(-)- 
0.16 dose groups (Figs. 7B, 7E, and 7F, respectively). There was no significant main 
effect of time or day, but a significant interaction of day*time-bin for the R(+) 0.02 dose 
group; F(5,40) = 3.014, p < .05. Post-hoc paired samples t-tests revealed that locomotor 
activity on the microinjection day (Day 5) was significantly lower than on the mock 
injection day (Day 4) only in the first 20-minute bin (Fig. 7C). There were no other 
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significant differences at each time-bin (p’s > .05). There was no significant main effect 
of time or day, but a significant interaction of day*time-bin for the R(+)- 0.04 dose group; 
F(1.98,15.84) = 4.448, p < .05. Greenhouse-Geisser statistics are reported because 
Mauchly’s Test for Sphericity was significant (p = .001). Post-hoc paired samples t-tests 
revealed that there were significant differences in locomotor activity during the 0-20 and 
21-40 minute time bins, with the animals moving less on the microinjection day (p’s 
< .05) (Fig. 7D). 
2.2.3. Saccharin Consumption 
Animal usage is detailed in Table 3. Forty-nine total animals were included in all 
aspects of the saccharin portion of this study. Out of those animals, all completed the 
study and were in dose groups included in the study. Of the 49 animals, 42 were 
successful bilateral hits of the AcbSh, giving a hit rate of 85.71% within the saccharin 
subset of animals. Only the successfully hit animals were included in the following 
analyses. 
The ANOVA on Days 1-4 acquisition data revealed no significant effect of day 
on acquisition of drinking; F(3,45) = 2.206, p > .05 (Fig. 8A). Total  two-hour saccharin 
drinking on Day 4 revealed no baseline differences in drinking between groups; F(4,41) = 
2.043, p > .05, data not shown. There were no effects of drug dose on total Day 5 
drinking; F(4,41) = 0.981, p > .05 (Fig 8B). 
The time course of saccharin intake was then statistically compared using a two-
way repeated measures ANOVA on Day 4 and Day 5 dose*time bins. There were no 
baseline differences in the time course of saccharin intake on Day 4; F(13.85,128.14) = 
1.194, p > .05 (Fig. 9A). Further, there were no differences in time course of intake on 
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Day 5; F(14.89,137.74) = 1.096, p > .05 (Fig. 9B). Greenhouse-Geisser statistics are 
reported for both of these repeated measures ANOVAs, as Mauchly’s Test of Sphericity 
was significant for each test (p’s < .01). 
Although there was no dose*time bin interaction, repeated measures ANOVAs 
were used to mirror locomotor activity analyses comparing Day 4 and Day 5 time course 
of drinking did reveal significant effects. The aCSF group displayed a main effect of day 
and time on drinking (p’s < .05), with consumption being lower on Day 5 and drinking 
being lower as time went on (Fig. 10A). There was no interaction between day*time bin 
(p > .05). The 0.02 R(+) group showed no effect of day or an interaction of day*time, but 
showed a main effect of time (p < .05) (Fig. 10B). The 0.04 R(+)- group had no main 
effects or interactions (p’s > .05) (Fig. 10C). The 0.08 S(-)- and 0.16 S(-)- groups 
revealed only an effect of day (p < .05), with animals consuming less saccharin following 
the microinjection versus the mock injection (Fig. 10D and 10E, respectively). 
2.2.4. Saccharin Locomotion 
As previously discussed, locomotor data was analyzed in two separate ways – to 
satisfy the agreed-upon statistics for this project as well as accurately characterize any 
changes in locomotor activity. To satisfy the agreed-upon statistics, Day 4 and Day 5 
total locomotor data was analyzed by an ANOVA. There were no differences between 
doses in Day 4 baseline total locomotor data; F(4,41) = 1.722; p > .01. There was a 
significant effect of dose on total Day 5 locomotor data; F(4,41) = 6.85, p < .01. Post-hoc 
t-tests revealed that the R(+)- 0.04 group displayed significantly higher total locomotor 
scores than all other dose groups (p’s < .05). Total locomotor activity data is not shown. 
Time course data were analyzed by a dose*time bin ANOVA on Day 4 and Day 5 
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locomotion. There was no interaction between time bin and dose on baseline locomotor 
data; F(11.65,104.88) = 0.757, p > .05. There was a significant interaction of time 
bin*dose on Day 5 locomotor scores; F(8.95,82.811) = 2.682, p < .01. Post-hoc one-way 
ANOVAs on each time bin revealed differences at the 61-80, 81-100, and 101-120 
minute time bins. Tukey’s post hoc tests revealed that the R(+)- 0.04 group showed 
significantly higher locomotor scores than all groups at the 61-80 minute time point, and 
higher scores than the aCSF, S(-)- 0.08, and S(-)- 0.16 groups at the 81-100 and 101-120 
minute time bins (p’s < .05)* (Fig. 12A).  
 One-way ANOVAs on Day 1-5 locomotor data for each dose revealed a 
significant effect of day for all dose groups except for the R(+)- 0.02 group (Fig. 11B). 
Tukey’s post-hoc tests revealed that Day 1 locomotor scores for the aCSF group were 
significantly higher than Days 2-5. Day 2 was also higher than Day 5 locomotor scores 
(Fig. 11A). For the R(+)- 0.04 group, Day 1 scores were significantly higher than Days 3 
and 4. Day 2 scores were also significantly higher than Days 3, 4, and 5 (Fig. 11C). For 
the S(-)- 0.08 group, Day 1 locomotion was significantly higher than Days 4 and 5, Day 2 
locomotion was significantly higher than Days 3, 4, and 5, and Day 3 locomotion was 
significantly higher than Day 5 (Fig. 11D). For the S(-)- 0.16 group, Day 2 locomotor 
scores were significantly higher than Days 1, 4, and 5. Day 3 locomotor scores were also 
higher than Day 5 scores (Fig. 11E). 
 To confidently assess the time course of locomotor behavior, Day 5 time course 
locomotion was compared to Day 4 time course locomotion for each group independently. 
Greenhouse-Geisser statistics are reported when Mauchly’s Test for Sphericity was 
significant (p < .05). For the aCSF group, there was only a main effect of day, with 
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locomotion being lower on the micro-injection day regardless of time bin (p < .05) (Fig. 
12A). There was also only a main effect of day for the S(-)- 0.08 group, with less 
locomotor activity following the microinjection (p < .05) (Fig. 12D). There were no main 
effects or interactions of day*time bin for the R(+)- 0.02, R(+)- 0.04, or S(-)- 0.16 groups 
(Figs. 12B, 12C, and 12E, respectively). While it appears in the graphs that there may 
have been some interactions in the locomotor data, these effects were not significant due 
to the use of Greenhouse-Geisser statistics for the R(+)- 0.04 and S(-)- 0.08 (p’s < .05). 
The S(-)- 0.16 dose group did not reach a significant interaction (p = .077). 
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CHAPTER 3 DISCUSSION 
3.1. Summary 
Overall, these data show that intra-AcbSh microinjection of R(+)- and S(-)- 
baclofen bidirectionally affect ethanol intake, but not saccharin consumption. Total 
ethanol intake is decreased by the high dose 0.04 µg R(+)-baclofen/side, but increased 
following microinjection of the high dose 0.16µg S(-)-baclofen /side. These drug effects 
also show a distinct time course of action, which is only partially reflected by changes in 
locomotor activity following microinjections of the drug. 
3.2 Locomotion 
The ethanol and saccharin data taken together suggest that locomotor activity is 
not predictive of reinforcer intake and vice versa If the reduction of ethanol intake by the 
high R(+)- dose was due to sedative effects, there also would have been a reduction in 
saccharin intake at the same dose. Therefore consumption data should be considered 
independent of the locomotor behavior. Further complicating the locomotor/consumption 
story is that the Acb itself plays a role in locomotor activity. Bilateral ablation of the Acb 
by 6-OHDA in rats abolished the locomotor response typically seen to a systemic 
amphetamine injection (Kelly et al., 1975). In a Pavlovian response paradigm, ablating 
the AcbSh completely abolished the effect of intra-Acb amphetamine injections on 
potentiating conditioned reinforcer responding without affecting Pavlovian or 
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instrumental conditioning (Parkinson et al., 1999). Parkinson et al., (1999) found that 
intra-Acb amphetamine injections in rats with an ablated core still showed increased 
potentiation of responding, but it was not specific to the reinforced lever, suggesting that 
alterations in locomotor activity are related to the AcbSh, but not core, and are not 
specific to goal-related activity. Increases of dopamine in the Acb have also been shown 
to increase locomotor activity, either through direct dopamine microinjection (e.g. 
Pijnenburg & van Rossum, 1973), or via alteration by another drug, such as nicotine (e.g. 
Benwell & Balfour, 1992) or cocaine (e.g. Delfs et al, 1990). This interaction is 
especially important, as baclofen may moderate locomotor activity via interaction with 
dopamine in a non-goal specific manner, yet possibly in a dose- and enantiomer-specific 
fashion. The role of dopamine in the AcbSh and its interaction with GABA will be 
discussed further on in this thesis. As already mentioned, the minimal locomotor effects 
observed do not represent a 1-to-1 relationship with ethanol or saccharin intake or effects 
on other behaviors, such as Pavlovian or instrumental response (Parkinson et al., 1999).  
3.3. Stereospecific Drug Action 
 The major highlight of these results is the stereospecific, bidirectional effects of 
the baclofen enantiomers on ethanol intake. The systemic work discussed in the rationale 
of this paper demonstrate that baclofen has these stereospecific effects when administered 
systemically, but this work specifically implicates the AcbSh as a target of interest for 
ethanol consumption. The specific role of the shell in addiction pathology will be 
discussed further on, with the current focus on a few other drugs that have shown 
stereospecific effects, which may elucidate the role of the separate baclofen enantiomers. 
Isozymes, which are enzymes that are functionally identical yet differ in amino acid 
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sequencing (Hunter & Markert, 1957), have been shown to be expressed differently 
across brain regions in monkeys, rats, and humans, potentially as a function of their 
binding affinity (Perez-Torres et al., 2000). The baclofen enantiomers are similar to 
isozymes in the sense that they are structurally different, yet functionally identical 
because they work as agonists at GABAB receptors. Stereospecific binding has been 
shown with other neurotransmitters and drugs in the rat brain, including norepinephrine 
and amphetamine (Coyle & Snyder, 1969).  
General differences in brain area binding are not a sufficient explanation in these 
experiments, where bidirectional behavior was observed following direct microinjection 
into one area of the brain. It is possible that the baclofen enantiomers are binding 
differentially in the same areas of the brain, and this may be the case in the AcbSh. For 
instance, Hill et al. (1988) showed that the orientation of aromatic and amine groups to 
the drug molecule of type 1 antiarrhythmic drugs is an important determinant of how the 
drug binds to the cardiac sodium channel of myocytes taken from Sprague Dawley heart 
tissue. Further, the antidepressant drug rolipram shows stereospecific high and low 
binding affinity (Schneider et al., 1986). Low-affinity binding of rolipram was 
demonstrated to be specific to one protein component of (R)-rolipram, which does not 
bind at high affinity sites (Rocque et al., 1997). Yet the high affinity rolipram binding 
sites mitigate the antidepressant effects of the drug (Zhang et al., 2006). However, the 
racemate and separate enantiomers of rolipram produce the same “feeling” or state of the 
animal, as they all substitute for each other in discriminative stimulus tasks (Schneider et 
al., 1995). Tangentially, the discriminatory stimulus findings of rolipram are interesting, 
as it has been shown that baclofen does not substitute for ethanol (Shelton & Balster, 
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1994). What is unknown is whether the enantiomers and racemic substitute for each other, 
or if the R(+)- enantiomer substitutes for ethanol, thereby reducing ethanol intake.  
 Mecamylamine, a nicotinic parasympathetic ganglionic blocker, is of great 
interest when working to interpret the current findings. Mecamylamine (Inversin) is used 
clinically to treat moderately severe to severe high blood pressure, yet was shown to be 
effective in reducing the rewarding effects of alcohol, alcohol-induced mood alterations, 
craving to consume alcoholic beverages, and decrease BECs following alcohol 
administration in a very small group of participants (N=17) that were not alcohol or 
nicotine dependent  (Blomqvist et al., 2002).  The separate enantiomers of 
mecamylamine have been relatively well studied. Nickell et al. (2013) reviewed the 
enantio-specific differences in behavior. S(+)- is a more effective anxiolytic than R(-)- in 
the light/dark box, forced swim test, and social interaction tests. S(+)- has also been 
shown to be more effective at blocking nicotine-induced seizures and decreasing 
spontaneous locomotor activity, yet both enantiomers are equally efficacious at altering 
nicotine-induced antinociception. Although R(-)- and S(+)- mecamylamine show no 
differences in affinity for nicotinic acetylecholine receptors (nAChRs) in rat whole 
membranes or in the ability of nicotine to alter binding, it has been suggested that S(+)- 
mecamylamine may work better at targeting nAChRs that are associated with  anxiolytic 
and antidepressant drug effects, while also displaying less side effects than R(-)- (Nickell 
et al., 2013). Interestingly, S(+)- mecamylamine is more efficacious at inhibiting low 
sensitivity nAChRs than R(-)- while also working as a positive allosteric modulator at 
high sensitivity nAChRs (Fedorov et al., 2009).  Receptor sensitivity is associated with 
affinity for nicotine and calcium permeability. Low sensitivity receptors show low 
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affinity for nicotine but high calcium permeability, while high sensitivity receptors 
display high nicotine affinity and low calcium permeability (Tapia et al., 2007). 
Taken together, the actions of baclofen may depend on whether high and low 
affinity GABAB receptors exist, whether R(+)- and S(-)- baclofen binding is preferential 
to one type of receptor over the other, and whether this affinity, sensitivity, or binding 
preference is related to behavioral effects of the drug. Unfortunately, the literature on 
baclofen binding does not really help to understand how the compounds used in the 
current study act at receptors. Binding of baclofen relies not only on the absolute 
configuration of the drug (d/l or S/R), but also on the rotation of the molecule (+ or -). 
Waddington and Cross (1980) showed that d- and l-baclofen (S- and R-, respectively) 
display no differences in displacing GABA in low-affinity crude membranes or in high-
affinity Triton membranes. Both enantiomers were much less effective at displacing 
GABA at high-affinity sites. Conversely, Bowery et al. (1983) looked at displacement of 
racemic baclofen in crude rat membrane. They found that GABA and (-)baclofen were 
equally able to displace the racemic mixture, whereas (+)baclofen displaced it to a much 
lesser extent. Drew et al. (1984) showed that, in the rat cerebellum, (-)baclofen binds 
more readily than the racemic mixture, and that it appears to bind to (-)baclofen selective 
sites. Yet Haas et al., (1985) showed that hyperpolarization of hippocampal CA1 cells is 
activated by R-, and not S-, baclofen. Further complicating issues, Karbon et al. (1984) 
suggest that there are anatomically distinct high and low affinity GABAB binding sites, 
and that low affinity sites are co-localized with cerebral cortical noradrenergic nerve 
terminals in the cow brain. While Waddington and Cross (1980) suggest that the non-
GABAergic effects of baclofen reside with the R- configuration, Karbon et al. (1984) 
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suggest that it is the (-)baclofen isomer that interacts with norepinephrine to potentiate 
the cAMP response in the rat cerebral cortex. At best, these literature sources suggest that 
the R- absolute configuration and the (-) molecular rotation appear to be important for 
binding affinity and interaction with other receptor systems in the brain. Yet, the mixtures 
used in this study combine the R- configuration with the (+) rotation, and the S- 
configuration with the (-) rotation, leading to an extremely muddled interpretation of 
binding and affinity results. In short, while it appears that R- and S- show no differences 
in binding to GABAB receptors, they may also be acting differentially with other systems. 
Contrarily, the (-) rotation is as efficacious as GABA at displacing racemic binding and 
also may be acting with other systems in the brain. Therefore, these specific compounds 
need to be looked at for binding and receptor selectivity before much headway can be 
made on their potential effects and interactions within the brain at a receptor level. 
3.4. Dopamine Involvement 
 Dopamine in the Acb has long been posited to play an important role in addiction 
pathology (Di Chiara et al., 1994). The “incentive arousal” view of dopamine response 
suggests that dopamine is not responsible for the behavioral reaction to the stimuli, but 
rather works as an amplifier signal for the stimuli – moderating whether or not the stimuli 
receives a response (Di Chiara et al., 2004). To elicit dopamine transmission in the 
AcbSh, a taste stimulus must not only have positive valence associated with it, but it must 
also be novel (Bassareo et al., 2002). It is believed that this normal dopamine response to 
a novel, positive stimulus becomes maladaptive in response to drugs of abuse (Di Chiara 
et al., 1994, Bassareo et al., 2003). For instance, dopaminergic responses are not elicited 
by presentation of sucrose following an active lever press (Carrillo & Gonzales, 2011), 
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and are not elicited by intraoral 20% sucrose infusion (Bassareo et al., 2002), even 
though when paired with ethanol both of these stimuli produce a dopaminergic response 
in the Acb. More specifically, Bassareo et al. (2003) gave rats a taste stimulant (20% 
sucrose + chocolate flavor), the taste stimulant + 10% ethanol, or 10% ethanol alone 
intraorally and looked at dialysate dopamine in the AcbSh. All three solutions showed an 
initial dopamine spike in response to the taste, with both ethanol solutions showing a 
secondary spike in dopamine related to the physiological effects of ethanol. To observe 
whether the dopaminergic response to ethanol was maladaptive, Bassareo et al. (2003) 
gave animals a chocolate and ethanol intraoral infusion pretreatment. Twenty-four hours 
later, a second oral ethanol infusion was given. Dialysate dopamine response showed that 
the initial dopamine response related to taste was absent, but the secondary dopamine 
response related to ethanol was stronger. These results suggest a habituation to the 
dopaminergic response to the tastant, but a maladaptive persistence in the response to the 
intracerebral effects of ethanol that the authors relate as a mechanism in developing 
behavioral responses to addictive drugs. Such effects have also been seen in the AcbSh 
with many other drugs of abuse. IV cocaine has been shown to increase extracellular 
dopamine in the shell, but not core of the Acb (Pontieri et al., 1996). Rats given the 
chance to self-administer cocaine have shown a trend for increased dopamine release in 
the shell over the core (Ito et al., 2000) and a statistically significant increase in dopamine 
levels in the shell over the core (Lecca et al., 2007). Long-term nicotine treatment in rats 
has been shown to decrease α6β2 nAChRs mediated dopamine release and the number of 
receptors in the AcbSh (Perez et al., 2013). Ahn and Phillips (2013) showed that 
amphetamine increased Acb dialysate dopamine efflux by 2000-2500%. These increases 
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were blocked by the dopamine transporter blockers GBR 12909 and methylphenidate. 
Further, mu opioid stimulation via DAMGO has been shown to be as effective as 
enhanced dopamine stimulation in increasing “wanting” of a sucrose solution, defined as 
cue-triggered response in a Pavlovian-Instrumental Transfer paradigm (Peciña & 
Berridge, 2013). Together, these results suggest that drugs of abuse and pharmacological 
interventions that do not directly target dopamine may interfere with the function of the 
dopamine system, thereby reducing or increasing salience of drug abuse. 
3.5. GABA Involvement 
 GABA is known to be largely present in the Acb, as well as to interact with 
ethanol and dopamine. Exposure to a single intra-gastric dose of ethanol showed 
increased activation of cells in the NAC shell, but not core over rats given a dose of water 
(Leriche et al., 2008). Of the reactive neurons, 80% were GABAergic. An increased in 
GABA receptors in the Acb has been seen in two strains of high alcohol preferring rats 
following four weeks of ethanol access (Hwang et al., 1990). As previously mentioned, 
one third of GABA receptors in the Acb are GABAB receptors (Bowery et al., 1987). 
Extrasynaptic GABAA receptors of the shell have been shown to play a role in ethanol 
intake (Nie et al., 2011; Rewal et al., 2009), and these results of the current experiments 
support the role of AcbSh GABAB receptors in ethanol intake. GABA and dopamine of 
the Acb are known to interact with each other. Within the Acb, 4% of tyrosine 
hydroxolase labeled, primarily dopaminergic, terminals were located on the soma of 
GABAergic neurons and another 14% formed junctions with GABAergic dendrites 
(Pickel et al., 1988). Through action on dopamine receptors located on GABAergic 
neurons, dopamine agonists have been shown to inhibit GABA release in the Acb (Beart 
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et al., 1979; De Belleroche & Gardiner, 1983). At low doses, neurotensin administered 
into the Acb has been shown to increase GABA release while decreasing dopamine 
release, whereas high doses have been shown to increase both GABA and dopamine 
(Tanganelli et al., 1994). 
 Therefore, it is proposed that the GABAergic actions of each baclofen enantiomer 
may be interacting with dopamine or other receptor types to exert effects on ethanol 
consumption. For example, Reynolds & Berridge (2001) showed that injection of 
muscimol (GABAA agonist) into the rostral AcbSh increased positive reinforcement 
feeding behavior but not defensive treading, whereas more caudal injections increased 
negative defensive treading behavior but did not affect feeding behavior. The authors 
suggest that this change in behavior may be dependent upon differential GABAergic 
interactions in each area, with more dopamine D1, D2, and opioid enkaphalin mRNA 
being present in the rostral shell, but more cholecystokinin, ACh, vasopressin, oxytocin, 
and norepinephrine and serotonin innervation in the caudal shell. 
Such interactions may explain the lack of drug effects seen on saccharin intake. If 
the actions of baclofen in the AcbSh are dependent upon interactions with cue-induced 
dopamine release, with the cue in this case being the daily introduction of the bottle, and 
there are no dopaminergic responses to the saccharin bottle on Day 5 (as would be 
suggested by Carrillo & Gonzales, 2011; Bassareo et al., 2002; 2003), baclofen would not 
be able to elicit effects on saccharin intake, as seen in this study. A secondary explanation 
may be a transfer of control of saccharin intake to a secondary area of the brain. Control 
of intake of a tastant that elicits an AcbSh dopaminergic response on Day 1 due to 
positive valence and novelty may be transferred to another brain area once the tastant is 
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no longer considered novel, as would be the case on Day 5 of intake. Bassareo et al. 
(2002) offer support for this theory by demonstrating that habituation of the dopamine 
response to the chocolate tastant occurred in the AcbSh, but not in the Acb core or the 
prefrontal cortex. Therefore, neurological control of non-addictive substances may be 
transferred to one of these two areas or elsewhere once novelty of the substance has worn 
off, suggesting that baclofen injections directly into the NAC core or prefrontal cortex on 
Day 5 may reduce saccharin intake. A third explanation of why baclofen was unable to 
reduce saccharin intake is the possibility that animals were willing to overcome drug 
effects to consume saccharin.  
A secondary consideration for interpreting the data is the GABAergic projections 
from the AcbSh. GABAergic efferents from the AcbSh project to the ventral pallidum 
and the VTA (Kalivas et al., 1993; Dray & Oakley, 1978). Both of these areas are 
believed to be involved in reinforcer directed behavior. Lesions of the anterior and 
posterior pallidum significantly reduce development of conditioned place preference for 
sucrose in rats kept at 90% of their free-feeding weight compared to sham lesioned 
animals (McAlonan et al., 1993). Lesioning the ventral pallidum also produces decreases 
in self-administration of cocaine and heroin (Hubner & Koob, 1990), while injections of 
mu or delta specific opiate receptor agonists into the caudal ventral pallidum have been 
shown to increase intracranial self-stimulation responses (Johnson et al., 1993; Johson & 
Stellar, 1994). 
A review by Kalivas (1993) reports unpublished data suggesting that 35-55% of 
projections from the Acb to the VTA are GABAergic, and that these efferent projections 
originate in the shell of the Acb, not the core. These projections synapse on both 
 
 
40 
dopaminergic and non-dopaminergic neurons, including GABAergic interneurons of the 
VTA. Kalivas suggests that inhibition of these GABA interneurons via GABAergic 
projections from the AcbSh and the pallidum may result in disinhibition of the VTA 
dopamine cells. Conversely, stimulation of D1 receptors by GABA projections from the 
AcbSh augments GABA release within the VTA and stimulates firing of GABAergic 
interneurons. 
There is some literature on how baclofen acts within the VTA. Tanner (1979) 
showed that baclofen microinjected into the VTA increased dialysate dopamine levels in 
the AcbSh. Kalivas et al. (1990) have also shown a similar effect; baclofen injected into 
the dopaminergic A10 region that is part of the VTA reduced dialysate dopamine 
response in the Acb to a systemic injection of mu opiate agonist in rats. Interestingly, 
inhibition of dopamine release in the VTA appears to be specific to GABAB receptors. 
Klitenick et al. (1992) showed that the GABAA agonist muscimol delivered directly into 
the VTA increased dialysate dopamine, whereas application of baclofen decreased 
dialysate dopamine. The authors propose that GABAA receptors inhibit GABAergic 
inputs to dopamine neurons due to their presynaptic location, whereas GABAB receptors, 
which are located on dopaminergic neurons, are directly inhibiting dopamine release. 
Moore & Boehm (2009) showed that direct injection of baclofen into the anterior, but not 
posterior, VTA reduced binge-like ethanol intake in the same DID paradigm used in this 
study. Again, these studies support that GABA is somehow interacting with dopamine to 
modulate ethanol consumption. 
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3.6. Drawbacks to DID 
 When interpreting the differences between drug effects on ethanol and 
saccharin intake, it is important to keep in mind that DID only accounts for consumption 
of the reinforcer. It does not account for the reinforcing value, as an operant paradigm 
would. This poses a problem for assessing whether the chosen reinforcers, ethanol and 
saccharin, are similarly reinforcing and whether drug effects are truly reinforcer specific, 
or if they are due to increased motivation to obtain saccharin. While mice freely ingest 
saccharin and a 0.2% solution is often used as a standard reinforcer control group (Lush, 
1984; Risinger et al., 1998; Yoneyama et al, 2008), minimal data exists on the reinforcing 
quality of different saccharin concentrations as seen in operant paradigms. One study 
(Risinger et al., 1998) found that animals responded 2.5 times more in an FR4 operant 
paradigm for a 0.2% w/v saccharin solution than a 20% v/v ethanol concentration.  
At a 0.2% w/v concentration, B6 mice have been shown to have between a 50% 
(Lush, 1984) to a 94.5% preference (Yoneyama et al., 2008). Preference, however, does 
not speak to how reinforcing a solution is. An animal may find a solution to be preferable, 
but may not actually work for that solution. This case is seen in Risinger et al. (1998); 0.2% 
saccharin and 20% ethanol have similar preference ratios, yet B6 mice work harder to 
receive saccharin. In an FR4 paradigm, B6 mice will respond 400 times for ethanol but 
respond 1000 times for saccharin in a 23 hr operant session. When 20% ethanol was 
given in a 0.2% saccharin, vehicle responding increased to almost 600 ethanol lever 
presses. The authors suggest that their results show that some of the effects in responding 
may be due to ethanol intoxication, while some are due to the higher reinforcing nature of 
saccharin, as seen by the increase in ethanol responding when saccharin was included. 
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Overcoming negative drug effects to consume saccharin would explain why animals 
drank even after receiving R(+)-baclofen, but it does not explain why S(-)-baclofen did 
not produce an increase in saccharin consumption. Further, systemic R(+)-baclofen 
reduced saccharin intake, so a blanket statement that R(+)-baclofen is unable to reduce 
saccharin consumption is unsatisfactory.  
Therefore, the best explanation is that the AcbSh is not responsible for the control 
of saccharin intake, likely due to a combination of a transfer of control to another brain 
region and the possible lack of dopamine response on Day 5. To test whether there is a 
transfer of control from the shell to the core, or elsewhere, baclofen injections could be 
given into the AcbSh on Day 1 to see if they block saccharin intake when dopamine is 
likely present as a response to the novelty of saccharin. Other regions of the brain, such 
as the Acb core and the prefrontal cortex, could also be targeted for Day 5 
microinjections to see if they reduce saccharin and/or ethanol consumption.  
3.7. Conclusions 
 In conclusion, the two aims of this study – to modulate consummatory behavior 
via intra-AcbSh injections of R(+)- and S(-)-baclofen – were met. Further, the hypothesis 
that R(+)- and S(-)-baclofen would bidirectionally alter ethanol intake, but not saccharin 
intake, was upheld. It is not likely that the effects of baclofen on consummatory behavior 
are related to locomotor activity, as activity counts did not track exclusively with 
consummatory behavior and should not be expected to, as an animal spending more time 
at the bottle would be more likely immobile. Unfortunately, due to equipment failure, 
using a simple ANOVA to show that groups do not differ in locomotor activity is not 
possible. Further, dopamine in the AcbSh plays a role in locomotor activity, and how that 
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role affected activity in these experiments cannot be identified. Overall, GABAergic 
interactions with dopamine in the shell may have contributed to the drug effects seen in 
this study. Maladaptive dopamine release in the AcbSh has been shown to occur with 
consumption of drugs of abuse, like ethanol, compared to dopamine response to simple 
tastants, like saccharin. This maladaptive dopamine release may be necessary for altering 
consummatory behavior, which may be why there is an effect of drug on ethanol, but not 
saccharin intake. When administered systemically, R(+)- baclofen reduces saccharin 
intake. Systemic administration may lead to these drugs acting elsewhere, like the Acb 
core or the prefrontal cortex where there is still release of dopamine in response of the 
tastant. The stereospecific effects of baclofen on ethanol intake may be related to a 
myriad of enantioselective properties like those seen in other compounds. These include 
differential binding to high/low affinity receptors which may influence differential 
receptor effects or which behaviors receptors may modify. Future studies within our lab 
could aim to target other brain areas, including the Acb core and the prefrontal cortex, to 
determine if injections of baclofen into these areas also affects ethanol intake and 
modulates saccharin intake. Work could be done using real-time PCR to assess 
differences in mRNA production following administration of the different enantiomers, 
whereas Western blotting could be used to assess protein changes. Further, 
immunohistochemistry could be used to identify if these enantiomers are binding 
differentially in the brain. Simple drug discrimination experiments should be used to 
assess if the three baclofen compounds substitute for each other, and whether each 
enantiomer substitutes for ethanol. Of great interest, but outside of the scope of our lab, is 
using microdialysis in awake behaving animals to assess how injections of R(+)- and S(-
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)- baclofen alter dopamine release in the shell. Currently, the Gonzales lab at the 
University of Texas at Austin, is working to develop microdialysis technique to identify 
GABA release in the brain (personal communication with Dr. Rueben Gonzales). Such 
advances in technology would present an amazing opportunity to advance the 
understanding of how GABA acts alone in the AcbSh to influence reinforcer 
consumption, and how it is interacting with dopamine and other neurotransmitters.  
Overall, these results continue to implicate the important role of the GABAB receptor in 
influencing ethanol intake. They also reinforce the notion that drugs exert 
enantioselective actions on behaviors, and that these actions are extremely important in 
considering the efficacy or potency of a drug for clinical treatment. This study has led to 
many more questions that are of great importance to the scientific field that can be 
answered in future research. 
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TABLES 
Table 1. Timeline of Experiment 
Surgery Recovery 
>48 Hours 
DID 
Day 1 
DID 
Day 2 
DID 
Day 3 
DID 
Day 4 
DID 
Day 5 
 Check 
cannula 
Check 
cannula 
Check 
cannula 
30 second 
restrain 
stress 
Mock 
microinjection 
Microinjection 
 
 
 
 
Table 2. Detailed breakdown of animals included in the ethanol experiments. *Includes 
exploratory doses of R+ 0.01, S- 0.24, S- 0.32. Hit rates were taken (9/9), but are not 
included in this table.**Animals which were lost before group assignment due to skull 
cap (3) or surgery error (8).***Animals lost after group assignment due to unused dose, 
compromised skull cap, failure to acquire ethanol intake, histology error, and in one case 
death following microinjection.   
Dose Hit Miss Other Loss*** Total 
aCSF 8 1 0 9 
R+ 0.02 9 3 9 12 
R+ 0.04 9 2 4 15 
S- 0.08 9 0 1 10 
S- 0.16 9 2 1 12 
Unused dose* n/a n/a 9 9 
Other** n/a n/a 11 11 
Total 44 8 26 78 
 
Table 3. Detailed breakdown of animals used in saccharin experiments. Asterisk (*) 
indicates animals lost after group assignment due to compromised skull cap, failure to 
acquire saccharin intake, or histology error. 
Dose Hit Miss Other Loss* Total 
aCSF 9 1 0 10 
R+ 0.02 7 3 0 10 
R+ 0.04 8 2 0 10 
S- 0.08 10 0 0 10 
S- 0.16 8 1 0 9 
Total 42 7 0 49 
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Figure 1. GABAergic projections to and from the AcbSh. 
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Figure 2. Groups included in this project. 
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Figure 3. Microinjection of R(+)- and S(-)-baclofen into the AcbSh bidirectionally affects 
ethanol consumption. A) Acquisition of ethanol drinking. B) Total two hour ethanol 
consumption is reduced by a 0.04 R(+)-baclofen dose, but increased by a 0.16 S(-)- 
baclofen dose compared to an aCSF microinjection. C) This bidirectional effect is also 
represented in the BECs immediately following intake on Day 5. D) BECs were strongly 
and significantly correlated with total ethanol intake. Asterisk (*)indicates significantly 
different than the aCSF group at p < .05. Asterisk (***) indicates significantly different 
than the aCSF group at p < .001. n’s = 8-9 per group. 
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Figure 4. Time course of ethanol intake following mock and microinjections. A) 
Following the mock injection, the time course of ethanol intake did not differ between 
dose groups. B) Following the microinjection, the time course of ethanol intake was 
significantly different between dose groups. Asterisk (*) indicates a significant follow up 
ANOVA p < .05 , n’s = 8-9 per group. 
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Figure 5. Time course of ethanol intake following the mock and microinjections for the 
aCSF (n=8) (A), R(+)- 0.02 (n=9) (B), R(+)- 0.04 (n=9) (C), S(-)- 0.08 (n=9) (D), and  
S(-)- 0.16 (n=9) (E) groups. Asterisk (*) indicates a significant difference between the 
mock and microinjection intake at that time point, p < .05. Plus sign (+) indicates a main 
effect of time, p < .05. Ampersand (&) indicates a main effect of day, p < .05. 
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Figure 6. Daily total two hour locomotor data for the aCSF (A), R(+)-0.02 (B), R(+)-0.04 
(C), S(-)-0.08 (D), and S(-)-0.16 (E) groups. Asterisk (*)indicates significantly different 
than Day 1, p < .05. Pound sign (#) indicates significantly different than Days 1 and 2, p 
< .05, n’s = 8-9. 
 
 
52 
 
 
Figure 7. Time course of locomotor activity in the ethanol animals. A) Time course of 
activity for all groups following Day 5 microinjection. Time course of locomotor activity 
following mock- compared to micro-injection days is shown for the aCSF (B), R(+)- 0.02 
(C), R(+)- 0.04 (D), S(-)- 0.08 (E), and S(-)- 0.16 (F) groups. Asterisk (*) indicates that 
locomotor activity following mock and micro-injection is significantly different, p < .05, 
n’s = 8-9 per group. 
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Figure 8. Effects of microinjection of R(+)- and S(-)-baclofen in the AcbSh on saccharin 
intake. A) Acquisition of saccharin intake. B) Microinjections of R(+)- and S(-)- baclofen 
do not alter ethanol intake compared to a microinjection of aCSF (n’s = 7-10 per group). 
 
 
Figure 9. Time course of saccharin intake following the Day 4 mock injection (A) and the 
Day 5 microinjection (B) showed no significant differences between dose groups (n’s = 
7-10 per group). 
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Figure 10. Saccharin consumption following mock (Day 4) versus microinjection (Day 5) 
for the aCSF (n=9) (A), R(+)- 0.02 (n=7) (B), R(+)- 0.04 (n=8) (C), S(-)- 0.08 (n=10) (D), 
S(-)- 0.16 (n=8) (E) groups. Plus sign (+) signifies a main effect of time, p < .05. 
Ampersand (&) signifies a main effect of day, p < .05. 
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Figure 11. Daily two hour locomotor data for the aCSF (A), R(+)- 0.02 (B), R(+)- 0.04 
(C), S(-)- 0.08 (D), and S(-)- 0.16 (E) groups. Asterisk (*) indicates significantly lower 
than Day 1, dollar sign ($) indicates significantly lower than Day 2, at sign (@)indicates 
significantly lower than Day 3, and pound sign (#) indicates significantly lower than 
Days 1 and 2, n’s = 7-10 per group. 
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Figure 12. The time course of locomotor data for each group following microinjection is 
graphed in Panel A. Asterisk (*) indicates that the R(+)- 0.04 group is displaying 
significantly more activity than all other groups. Pound sign (#) indicates that the R(+)- 
0.04 group is displaying significantly more activity than the aCSF, S(-)- 0.08, and S(-)- 
0.16 groups. The time course of locomotor activity following mock-and microinjections 
for aCSF (B), R(+)- 0.02 (C), R(+)- 0.04 (D), S(-)- 0.08 (E), and S(-)- 0.16 (F) groups is 
also shown. Ampersand (&) indicates a main effect of day, n’s = 7-10 per group
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